• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Forbion (Group)

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 69 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. *

 

	Start	2006-12-01 splitoff
	Today	Forbion Capital Partners (NL)
	Predecessor	ABN AMRO Capital Life Sciences
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Slootweg, Sander (Forbion Capital Partners 20111 Managing Partner before ABN AMRO Capital)
	Person 2	Kersten, Dirk (Forbion 201810– General Partner before Inkef Capital + Gilde Healthcare)
	Region	Naarden
	Country	Netherlands
	Street	2-35 Gooimeer
	City	1411 DC Naarden
	Tel	+31-35-699-3000
		Address record changed: 2021-04-24
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	1,700,000,000 (capital under management (2021) 2021-03-01)
		* Document for �About Section�: Forbion Capital Partners. (4/16/21). "Press Release: Forbion Appoints Head of Communications". Amsterdam.
		Record changed: 2021-12-18

Advertisement

More documents for Forbion (Group)

• [1] Forbion Capital Partners. (3/31/22). "Press Release: Forbion Appoints Both Dr Ton Logtenberg and Dr Michael Hayden as Venture Partners". Naarden....
• [2] Forbion Capital Partners. (3/14/22). "Press Release: Forbion Strengthens Its Team with the Appointments of Mathias Vinther and Vanessa Carle". Naarden....
• [3] Complement Therapeutics Ltd.. (2/23/22). "Press Release: Complement Therapeutics Ltd Raises EUR 5 Million Seed Financing by BGV and Forbion and Appoints Dr Rafiq Hasan as CEO". London....
• [4] Anaveon AG. (12/16/21). "Press Release: Anaveon to Raise CHF 110 Million in Oversubscribed Series B Financing". Basel....
• [5] Forbion Capital Partners. (12/9/21). "Press Release: Forbion European Acquisition Corp. Announces Pricing of $110 Million Initial Public Offering". Naarden....
• [6] Forbion Capital Partners. (10/14/21). "Press Release: Forbion Co-leads New Investment in Rectify Pharmaceuticals Which Launches with $100m Series A Financing". Cambridge, MA....
• [7] Oxitope Pharma B.V.. (9/16/21). "Press Release: Launch of Oxitope Pharma, a Biopharmaceutical Start-up Dedicated to the Discovery and Development of Antibody-based Medicines for the Treatment of Diseases Caused by Oxidative Stress". Amsterdam....
• [8] Forbion Capital Partners. (9/16/21). "Press Release: Forbion Launches Portfolio Company Oxitope Pharma Focused on Inflammatory, Cardiovascular and Fibrotic Diseases". Naarden....
• [9] Forbion Capital Partners. (9/1/21). "Press Release: Forbion Appoints Nanna Lüneborg as a General Partner". Naarden....
• [10] Mestag Therapeutics Ltd.. (8/3/21). "Press Release: Mestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures". Cambridge....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.